Director's Message

The Feinberg Neuroscience Institute promotes integrated and multidisciplinary approaches to facilitate early discovery and development of targeted therapies for patients with neuropsychiatric disorders. A deep understanding of disease mechanisms provides the foundation for effective systematic identification of biomarkers and therapeutic targets in neuropsychiatric disorders.

For CNS disorders, the path to elucidation of disease mechanisms, discovery of biomarkers, and nomination of therapeutic targets is highly dependent on human genetics. Identification of strong associations between genetic variants and disease states further enables identification of disease-relevant molecular pathways influenced by the variant.

Collaborative efforts have been established across academic and government institutions, industry, and voluntary organizations to develop shared resources for discovery research and clinical trials.

We believe that through these collaborations we have the potential to find treatments for many incurable neuropsychiatric disorders. We owe this to those who suffer from these disorders and to patients’ families.

Dimitri Krainc, MD, PhD
Director, Feinberg Neuroscience Institute
Director, Simpson Querrey Center for Neurogenetics
Chair, Davee Department of Neurology
Aaron Montgomery Ward Professor of Neurology